AI-empowered diagnostic retina scans can help prevent heart and kidney diseases
November 10th 2022Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.
Read More
Harrow rolls out ordering portal for atropine formulations
November 10th 2022According to the company, compounded formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. The prescriptions will be dispensed through Harrow’s wholly owned subsidiary, ImprimisRx.
Read More
Nicox outlines future development, partnership plans for NX 470 in glaucoma
November 7th 2022The company said it plans to generate clinical data aiming to demonstrate the potential retinal benefits of NCX 470 in order to add significant therapeutic value to the product profile in glaucoma.
Read More
Viatris making ophthalmology push with acquisition of Oyster Point Pharma
November 7th 2022Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of Tyrvaya nasal spray and its ophthalmology pipeline.
Read More
Apellis to submit 24-month phase 3 data to FDA for pegcetacoplan NDA for geographic atrophy
November 4th 2022According to Apellis Pharmaceuticals, the submission will be a Major Amendment to the NDA, extending the review period by three months with an expected PDUFA target action date in February.
Read More
RGX-314 continues to be well tolerated in 50 patients from Cohorts 1-3 with no drug-related serious adverse events. The Phase II trial will be expanded to include higher third dose level, with patients stratified by DRSS levels across cohorts and all receiving short-course prophylactic ocular steroids following RGX-314 administration.
Read More
Altris unveils artificial intelligence platform for automated OCT scans analysis
November 2nd 2022The company's AI cloud-based platform is available via a browser to any eye care professional in the world. The artificial intelligence algorithm was trained on millions of graphically labeled OCT scans collected from ophthalmic clinics.
Read More
KYS Vision: clinical outcomes of remote physiologic monitoring for chronic retinal conditions
November 1st 2022The study is one of the first clinical trials to validate the clinical utility of real-world remote physiologic monitoring using an on-demand vision-as-a-service extension to the specialty retina clinic to enable remote monitoring of patients with chronic diseases such as AMD, diabetic retinopathy, and other retinal conditions.
Read More
Study: Focusing on small incision garden hydroaspiration of iris lesions
October 27th 2022Arun Singh, MD, discusses a presentation on iris lesions he gave recently at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago on the use of small incision garden hydroaspiration of iris lesions.
Read More